On November 10, 2020 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported that its President and Chief Executive Officer, Christopher J. Schaber, PhD, will deliver a corporate presentation at the upcoming virtual investor conferences below (Press release, Soligenix, NOV 10, 2020, View Source [SID1234570562]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Virtual Fall Investor Summit held on November 16 through 18, 2020, with presentations, one-on-one meetings, round tables, and networking. The Soligenix presentation will be held on Tuesday, November 17 at 9:30AM ET. To view the live webcast, please visit View Source For more information about the Virtual Investor Summit, please refer to the conference website at View Source
A.G.P.’s Virtual Healthcare Symposium on November 19, with one-on-one meetings and executive panels throughout the day. For more information about the A.G.P. Virtual Healthcare Symposium, please refer to the conference website at View Source